Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs and make a difference in their lives. Our Noble Purpose is at the core of our work: “Transform the patients' world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.
Founded in 1943 and headquartered in Barcelona, the company is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 78-year history, Almirall has retained a strong focus on the needs of patients. Almirall has currently direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries. The company has nearly 1,800 employees.
Role within BIOMAP
Almirall will contribute to BIOMAP by providing biosignatures operating in the different stages of atopic dermatitis patients (skin immune cell composition, skin transcriptome and systemic biomarkers) and coordinating bioanalysis of BIOMAP samples through specialised CROs. The company will furthermore provide dedicated resources to the project in the form of scientific and dermatological expertise as well as data analysis. Almirall specialises in Medical Dermatology, being atopic dermatitis and psoriasis two of its core skin disease areas.